IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
The University of British Columbia [2020] APO 15
Patent Application: 2015202689
Title:14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
Patent Applicant: The University of British Columbia
Delegate:Dr S.D. Barker – Deputy Commissioner of Patents
Decision Date: 20 March 2020
Hearing Date: Written submissions filed on 28 September 2017
Catchwords: PATENTS – objections under section 40 raised during examination – grounds cannot be maintained – directed to return to examination for consideration of the grounds of novelty and inventive step
Representation: Patent attorney for the applicant: Griffith Hack
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2015202689
Title:14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
Patent Applicant: The University of British Columbia
Date of Decision: 20 March 2020
DECISION
The grounds of objection raised by the examiner cannot be maintained.
The application cannot proceed to acceptance because there has not yet been an examination in relation to novelty and inventive step. I direct that examination of these grounds take place as expeditiously as possible.
REASONS FOR DECISION
The present matter is governed by the Patents Act 1990 as amended by the IP Laws Amendment (Raising the Bar) Act 2012.
At the outset I note that there has been a lengthy period between the applicant requesting a hearing in this matter and the issuing of this decision. I regret the delay and any inconvenience caused by that delay.
Patent application 2015202689 is a divisional of patent 2008329529. The application is presently undergoing examination. A third report issued on 7 September 2017, maintaining the grounds of objection of clear enough and complete enough disclosure, support and best method of performance (section 40(2) and 40(3)). The grounds of novelty and inventive step were reserved pending resolution of the section 40 matters. The applicant asked to be heard in relation to the objections under section 40.
The technology of the application is antibodies. The antibodies have the property that they "specifically bind to the eta isoform of the 14-3-3 protein and are capable of discriminating between the eta isoform and other 14-3-3 protein isoforms".[1] The description (and claims) refer to raising antibodies against antigens having SEQ ID NOs 1-32 as set out in the specification. The antibodies are said to have utility in determining the presence of 14-3-3 eta protein and in the diagnosis of conditions including arthritis. The claims as most recently proposed to be amended are directed to methods of determining the presence of the eta protein in a sample using the antibodies, and kits containing an immobilised antibody.
[1] Specification at page 1.
Section 40(2)(a) – clear enough and complete enough disclosure
Section 40(2)(a) sets out the requirement that a specification must
disclose the invention in a manner which is clear enough and complete enough for the invention to be performed by a person skilled in the relevant art
The Deputy Commission in Evolva SA[2] (Evolva) said of this provision:
"In general, the extent…
Keep reading for free
Create a free CaseChat account to read The University of British Columbia and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2020] APO 15
- Decision Date
CaseChat Overview and Summary
The central legal issue the court was required to address was whether the Commissioner's objections under section 40 of the Patents Act could be maintained. Specifically, the court needed to determine if the objections related to the novelty and inventive step of the invention were valid and if the objections could be sustained given the evidence and arguments presented by both parties. The university argued that the objections were misconceived and should not have been raised, while the Commissioner maintained that the objections were valid and should be considered.
The court found that the objections raised by the Commissioner were misconceived and could not be maintained. The court held that the objections were not relevant to the examination of the patent application and did not address the actual merits of the invention. The court also found that the Commissioner had not provided sufficient evidence to support the objections, and the objections were therefore not valid. As a result, the court directed the Commissioner to return to the examination of the patent application for consideration of the grounds of novelty and inventive step. The court held that the Commissioner should reconsider the invention in light of the evidence and arguments presented by the university and make a fresh determination on the merits of the invention.
The final orders of the court were that the objections raised by the Commissioner under section 40 of the Patents Act were not valid and could not be maintained. The court directed the Commissioner to return to the examination of the patent application and reconsider the invention on the grounds of novelty and inventive step. The court also ordered that the Commissioner pay the university's costs of the proceeding.
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi